Agrawal, R, Tan, SL, Wild, S et al. (1999). Serum vascular endothelial growth factor concentrations in in-vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71:278–93.CrossRefGoogle ScholarPubMed

Agrawal, R (2003). What's new in the pathogenesis and prevention of ovarian hyperstimulation syndrome?Hum Fertil (Camb) 3:112–15.CrossRefGoogle Scholar

Artini, PG, Fasciani, A, Monti, M et al. (1998). Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 70:560–4.CrossRefGoogle Scholar

Asch, RH, Li, HP, Balmaceda, JP et al. (1991). Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groupsHum Reprod 6:1395–9.CrossRefGoogle ScholarPubMed

Blankenstein, J, Shalev, J, Saadon, T et al. (1987). Ovarian hyperstimulation syndrome prediction by number and size of preovulatory ovarian follicles. Fertil Steril 47:597–602.CrossRefGoogle Scholar

Chen, CD, Chen, HF, Lu, HF et al. (2000). Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 15:1037–42.CrossRefGoogle ScholarPubMed

D'Ambrogio, G, Fasciani, A, Monti, M et al. (1999). Serum vascular endothelial growth factor levels before starting gonadotrophin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome. Gynecol Endocrinol 13:311–15.CrossRefGoogle ScholarPubMed

D'Angelo, A, Davies, R, Salah, E et al. (2004). Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study. Fertil Steril 81:332–6.CrossRefGoogle ScholarPubMed

Daelemans, C, Smits, G, Maertelaer, V et al. (2004). Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle stimulation hormone receptor Ser 680 Asn polymorphism. J Clin Endocrinol Metab 89:6310–15.CrossRefGoogle Scholar

Danninger, B, Brunner, M, Obruca, A et al. (1996). Prediction of ovarian hyperstimulation syndrome of baseline ovarian volume prior to stimulation. Hum Reprod 11:1597–9.CrossRefGoogle Scholar

Delvigne A (2004). Epidemiology and pathophysiology of ovarian hyperstimulation syndrome. In (Gerris, G, Olivennes, F, De Sutter, P, Eds), Assisted Reproductive Technologies: Quality and Safety. New York: Parthenon Publishing, Chapter 12, pp. 149–62.

Delvigne, A, Demoulin, A, Smitz, J et al. (1993a). The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicenter study. I. Clinical and biological features. Hum Reprod 8:1353–60.CrossRefGoogle Scholar

Delvigne, A, Dubois, M, Battheu, B et al. (1993b). The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicenter study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 8:1361–6.CrossRefGoogle Scholar

Enskog, A, Nilsson, L & Brannstrom, M (2000). Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod 15:532–8.CrossRefGoogle ScholarPubMed

Enskog, A, Nilsson, L & Brannstrom, M (2001). Plasma levels of free vascular endothelial growth factor (165) (VEGF 165) are not elevated during gonadotrophin stimulation in in-vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 96:196–201.CrossRefGoogle Scholar

Friedman, CI, Seifer, DB, Kennard, EA et al. (1998). Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertil Steril 64:268–72.Google Scholar

Geva, E, Amit, A, Lessing, JB et al. (1999). Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome?J Reprod Med 44:91–6.Google ScholarPubMed

Haning, RVAustin, CWJr, Carlson, IH et al. (1983). Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 40:31–6.CrossRefGoogle ScholarPubMed

Haning, RV, Strawn, EY & Nolten, WE (1985). Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 66:220–4.Google ScholarPubMed

Karam, KS, Taymor, ML & Berger, MJ (1973). Estrogen monitoring and the prevention of ovarian overstimulation during gonadotrophin therapy. Am J Obstet Gynecol 115:972–7.CrossRefGoogle Scholar

Lass, A, Vassiliev, A, Decosterd, G et al. (2002). Relationship of baseline ovarian volume to ovarian response in World Health Organization Group II anovulatory patients who underwent ovulation induction with gonadotropins. Fertil Steril 78:265–9.CrossRefGoogle Scholar

Ludwig, M, Jelkmann, W, Bauer, O et al. (1999). Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 14:2437–41.CrossRefGoogle ScholarPubMed

Mathur, R, Hayman, G, Bansal, A et al. (2002). Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertil Steril 78:1154–58.CrossRefGoogle ScholarPubMed

Moohan, JM, Curcio, K, Leoni, M et al. (1997). Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome. Fertil Steril 57:728–32.CrossRefGoogle Scholar

Morris, RS, Paulson, RJ, Sauer, MV et al. (1995). Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod 10:811–14.CrossRefGoogle ScholarPubMed

Ogawa, S, Minakami, H, Araki, S et al. (2001). A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. J Assist Reprod Genet 18:114–19.CrossRefGoogle ScholarPubMed

Pellicer, A, Albert, C, Mercader, A et al. (1999). The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6 and vascular endothelial growth factor. Fertil Steril 71:482–9.CrossRefGoogle ScholarPubMed

Quintana, R, Kopcow, L, Marconi, G et al. (2001). Relationship of ovarian stimulation response with vascular endothelial growth factor and degree of granulosa cell apoptosis. Hum Reprod 16:1814–18.CrossRefGoogle ScholarPubMed

Rizk B (1992). Ovarian hyperstimulation syndrome. In (Brinsden, PR, Rainsbury, PA, Eds), A Textbook of In-vitro Fertilization and Assisted Reproduction. Carnforth, UK: Parthenon Publishing, pp. 369–83.Google Scholar

Rizk B (1993). Ovarian hyperstimulation syndrome. In (Studd, J, Ed.), Progress in Obstetrics and Gynecology. Edinburgh: Churchill Livingstone, Vol.11, Chapter 18, pp. 311–49.Google Scholar

Rizk B (2001). Ovarian hyperstimulation syndrome: prediction, prevention and management. In (Rizk, B, Devroey, P, Meldrum, DR, Eds), Advances and Controversies In Ovulation Induction. 34th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 57th Annual Meeting, Orlando, FL, pp. 23–46. Published by the American Society for Reproductive Medicine.Google Scholar

Rizk B (2002). Can OHSS in ART be eliminated? In (Rizk, B, Meldrum, D, Schoolcraft, W, Eds), A Clinical Step-by-Step Course for Assisted Reproductive Technologies. 35th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 58th Annual Meeting, Seattle, WA, pp. 65–102. Published by the American Society for Reproductive Medicine.Google Scholar

Rizk, B & Aboulghar, M (1991). Modern management of ovarian hyperstimulation syndrome. Hum Reprod 6:1082–7.CrossRefGoogle ScholarPubMed

Rizk B & Aboulghar MA (2005). Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In (Brinsden, P, Ed.), A Textbook of In-vitro Fertilization and Assisted Reproduction, Third Edition. London: Parthenon Publishing, Chapter 12, pp. 217–58.CrossRefGoogle Scholar

Rizk B & Nawar MG (2004). Ovarian Hyperstimulation Syndrome. In (Serhal, P, Overton, C, Eds), Good Clinical Practice in Assisted Reproduction. Cambridge, UK: Cambridge University Press, Chapter 8, pp. 146–66.CrossRefGoogle Scholar

Rizk, B & Smitz, J (1992). Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 7:320–7.CrossRefGoogle ScholarPubMed

Rizk, B, Aboulghar, MA, Smitz, J et al. (1997). The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3:255–66.CrossRefGoogle ScholarPubMed

Smith, BH & Cooke, ID (1991). Ovarian hyperstimulation: actual and theoretical risks. Comment. BMJ 302:127–8.CrossRefGoogle Scholar

Tal, J, Faz, B, Samberg, I et al. (1985). Ultrasonographic and clinical correlates of menotrophin versus sequential clomiphene citrate: menotrophin therapy for induction of ovulation. Fertil Steril 45:342–9.CrossRefGoogle Scholar

Thomas, K, Searle, T, Quinn, A et al. (2002). The value of routine estradiol monitoring in assisted conception cycles. Acta Obstet Gynecol Scand 81:554–5.CrossRefGoogle ScholarPubMed

Todorow, S, Schricker, S, Siebzehnruebl, E et al. (1993). Von Willebrand factor: an endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome. Hum Reprod 8:2039–46.CrossRefGoogle ScholarPubMed

Tozer, AJ, Iles, RK, Iammarrone, E et al. (2004). The effects of ‘coasting’ on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod 19:522–8.CrossRefGoogle ScholarPubMed